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Management of Neuroendocrine liver metastases (NELM) is challenging. The presence of NELM worsens survival outcome and
almost 10% of all liver metastases are neuroendocrine in origin. There is no ﬁrm consensus on the optimal treatment strategy
for NELM. A systematic search of the PubMed database was performed from 1995–2010, to collate the current evidence and
formulate a sound management algorithm. There are 22 case series with a total of 793 patients who had undergone surgery for
NELM. The overall survival ranges from 46–86% at 5 years, 35–79% at 10 years, and the median survival ranges from 52–123
months. After successful cytoreductive surgery, the mean duration of symptom reduction is between 16–26 months, and the 5-
year recurrence/progression rate ranges from 59–76%. Five studies evaluated the eﬃcacy of a combination cytoreductive strategy
reporting survival rate of ranging from 83% at 3 years to 50% at 10 years. To date, there is no level 1 evidence comparing surgery
versus other liver-directed treatment options for NELM. An aggressive surgical approach, including combination with additional
liver-directed procedures is recommended as it leads to long-term survival, signiﬁcant long-term palliation, and a good quality of
life. A multidisciplinary approach should be established as the platform for decision making.
1.Introduction
Neuroendocrine tumors (NETs) are a varied group of
neoplasms characterized by a relatively slow growth rate and
the potential to produce and secrete a variety of hormones
along with other vasoactive substances, giving rise to a
variety of clinical syndromes. Neuroendocrine tumors are
relatively uncommon with an approximate incidence of 1 to
5 per 100,000, but there has been a slow but steady rise in its
incidence and prevalence [1, 2]. In the USA,the Surveillance,
Epidemiology, and End Results (SEER) database showed a
signiﬁcant increase in reported incidence from about 1 in
100,000 in 1973 to 5 in 100,000 in 2004 [3]. Overall, the
incidence is increasing at a rate of 3% to 10% per year [4].
This increase was likely caused in part by improvements in
classiﬁcation of these tumors, and the widespread use of
endoscopy for cancer screening likely also contributed to the
increase in reported incidence of gastrointestinal NETs [3].
Neuroendocrine tumors include carcinoid tumours, gas-
trinomas, insulinomas, glucagonomas, somatostatinomas,
and vipomas [5]. Histopathologically, NETs are tumours of
cells, which originate from the neuroectoderm and possess
secretory granules. They can occur as part of multiple en-
docrine neoplasia type 1 (MEN type I) syndrome, or more
oftentheyoccurinisolation.Anatomically,theyareclassiﬁed
according to their site of origin as foregut (including lung),
midgut, or hindgut tumours. Clinically, they can be classiﬁed
as either functional tumors or as nonfunctional tumors
[6, 7].
The natural history of NETs is highly variable, and
clinical management is challenging. Over the past three
decades, the understanding of neuroendocrine tumors has
been improved signiﬁcantly by the elucidation of its tumor
biology, advances in surgical and perioperative care, and the
development of novel diagnostic methods, but the survival
of patients with NETs has not improved appreciably in either
the USA or UK [1, 8].
About 85% of NETs originate from the gastrointestinal
tract, and the majority of patients present at diagnosis
with metastases. Liver is the most common organ involved,
followed by bone and lung [9, 10]. Almost 10% of all liver
metastases are neuroendocrine in origin [11–14]. Neuroen-
docrine liver metastases (NELM) occur in 50% to 75% of2 International Journal of Hepatology
small-bowel carcinoids, 5% to 70% of foregut carcinoids,
and about 14% of hindgut carcinoids [1, 10]. Up to 85%
of NETs have hepatic metastasis (Up to 87% present as
synchronous lesions; about 10% as metachronous lesions),
and they are potentially completely resectable in only 7% to
15% of patients [10, 15].
The presence of neuroendocrine liver metastases worsens
survival outcome. There are many treatment strategies that
have been attempted over the years for metastatic NETs.
These include surgery, locoregional directed therapies such
as radiofrequency ablation (RFA), hepatic artery emboliza-
tion, and transarterial chemoembolization (TACE). These
are often used in combination with other systemic ther-
apy such as somatostatin analogues, various chemotherapy
regimes, and most recently, peptide receptor radionuclide
therapy (PRRT).
In this paper, we review the current literature and discuss
on the surgical aspects of the management of neuroen-
docrine liver metastases. The spectrum of hepatic surgical
procedures comprised complete resections of various extent
(including hilar lymphadenectomy), palliative cytoreductive
resection, and orthotopic liver transplantation (OLT). The
aim of this paper is to collate the available and current
information on the management of neuroendocrine liver
metastases, to formulate a sound management algorithm,
and to promote discussion regarding the role of surgical
resection for NELM in these patients.
2. Surgeryfor NeuroendocrineLiverMetastases
There are more reports of patients undergoing surgery for
NELM over the past decade than ever before; this is a
testament to the increasing acceptance of the aggressive
surgical attitude and its associated beneﬁts towards manage-
ment of NELM [16]. More than 2 decades ago, the Mayo
Clinic, in their review of all their patients with carcinoid
tumors treated between 1970 and 1989, fewer than 10%
underwent cytoreductive hepatic surgery for metastases (n =
37) [17]. In 1986, Galland and Blumgart found only two
candidates for suitable hepatic surgery among 30 patients
with NETs [18]. Sarmiento et al. in a 2002 review paper
on NELM, performed a literature search of the English
language medical literature from 1973 to 1999, and this
revealed a total of only 57 patients who undergone partial
hepatectomy for NELM. This is in contrast to another more
recent study from the Mayo Clinic group, they reported 170
patients who undergone surgical resection for NELM from
1977 to 1998 [19]. Another recent study comparing liver
resection versus intra-arterial therapy for NELM involving
nine institutions, they reported more than 300 patients who
undergone surgery for NELM [20].
The gold standard for evidence-based clinical practice
remains unbiased large prospective randomised controlled
trials. A multi-institutional collaborative trial conducted
over many years may be necessary to recruit patients
to compare surgery versus other liver-directed treatment
options for NELM, for example, RFA, TACE, and OLT, a
study like this will require a minimum of 776 patients in
order for it to be powered to detect a diﬀerence of 10% in
survival rate (based on alpha of 0.05 and power of 0.8) [21].
In view of the highly selective nature of patients undergoing
either hepatic resection or OLT, randomized controlled trials
evaluating patient outcomes with these treatment modalities
would likely be diﬃcult to perform. However, it is important
to highlight that due to the paucity of cases even in large
institutions and the nonrandomized uncontrolled nature of
these studies, there will be biases; the encouraging survival
outcomes observed in surgically treated patients may be
related to inherently favorable prognostic factors such as low
tumor burden.
In the literature, many deﬁne curative resection diﬀer-
ently. In some studies, curative intent is deﬁned only with
a R0 resection achieved, whereas others classify resection
as complete without referring to the margin status, and
others deﬁned a curative procedure when all visible gross
disease was removed [22]. Despite the armamentarium of
treatment options and an ill-deﬁned optimal management
protocol, surgical resection of neuroendocrine liver metas-
tases (NELM), if achievable, is generally considered as the
best option of both cure and palliation of symptoms [23].
3. Curative Liver Resection for Neuroendocrine
LiverMetastases
In the principles of surgical oncology, curative resection is
deﬁned as the complete removal of tumour tissues with a
clear resection margin on pathological examination (hepatic
and extrahepatic R0 status). Liver resection for metastatic
disease has gained wide acceptance as a potentially curative
option in patients with colorectal cancer [19, 24, 25]. With
improvements in the safety of major hepatic resection and
an operative mortality rate of about 5% in most series, there
has been an increasing role of liver resection for a potential
cure of metastatic disease from neuroendocrine tumors.
3.1. Results of Curative Liver Resection for Neuroendocrine
Liver Metastases. Surgery for NELM is the standard against
all other forms of liver-directed or systemic therapies. Due to
the relative low incidence, the biological heterogeneity NETs,
and NELM, there is a lack of prospective randomized studies
providing level 1 evidence. Based on encouraging results
from large retrospective studies and cumulative experience,
radical surgery including resection of the primary tumour
and the liver metastases has been the main treatment for
potentially resectable advanced neuroendocrine tumours
metastatic to the liver.
Patients with untreated hepatic metastases have a 5-
year survival of approximately 20% to 40% [23, 26]. As a
result, many studies have advocated aggressive surgery for
NELM with the aim of extending survival (Tables 1 and 2)
[19, 23, 26–33]. Due to the indolent nature of the disease,
the overall survival is still very good after hepatic resection.
This holds true even in stage-4 disease and notwithstanding
a high post-curative resection 5-year recurrence rate of more
than 40–70% in most series. The overall survival ranges
from 46 to 86 percent at 5 years and 35 to 79 percent at 10
years [19, 23, 26, 29, 30, 32, 34–36]. The major studies ofInternational Journal of Hepatology 3
Table 1: Case series of hepatic resections performed for neuroendocrine liver metastases published in the past 15 years. The following table
summarizes the results of modern-day series of liver resections performed for neuroendocrine tumors liver metastases.
Author Year
N under-
going
resection
Percentage of
curative and
palliative
resections
Operative
mortality
(%)
Operative
morbidity (%)
Symptom
control
(%)
Survival (% is for 5-year survival if
not otherwise stated)
(1) Que et al. [13] 1995 74 38% curative
62% palliative 2.7 24 90
73% at 4 years
Similar survival rates between
curative versus palliative resection
(2) Dousset et al. [35] 1996 17 71% curative,
29% palliative 5.9 23.5 88 46% at 5 years (overall)
62% at 5 years (curative)
(3) Ahlman et al. [16] 1996 54 22% curative,
78% palliative 0 NA 100 70% at 5 years
(4) Chen et al. [26] 1997 15 100% curative 0 NA NA 73% at 5 years
(5) Chamberlain et al.
[23] 2000 34 44% curative,
56% palliative 6 NA 100
76% at 5 years
Diﬀerences in survival between
curative/palliative resections are
not reported
(6) Grazi et al. [30] 2000 19 84% curative,
16% palliative 0 NA NA 92.6% at 4 years
(7) Sarmiento et al. [19] 2001 170 44% curative,
56% palliative 1.2 4.1 96
61% at 5 years;
35% at 10 years
Diﬀerences in survival between
curative and palliative resections
are not reported
(8) Yao et al. [32] 2001 16 100% curative 0 12 NA 70% at 5 years
(9) Coppa et al. [36] 2001 20 100% curative NA NA NA 67% at 5 years
(10) Jaeck et al. [103] 2001 13 NA 0 NA 100 68% at 6 years
(11) Nave et al. [33] 2001 31 32% curative,
68% palliative 01 3 N A
47% at 5 years
86% for curative resections, 26%
for palliative resections
(12) Dejong et al. [104] 2002 5 NA 0 20 NA Median survival 59 months
(13) Norton et al. [28] 2003 16 100% curative 0 19 100 82% at 5 years
(14) Elias et al. [29] 2003 47 53% curative,
47% palliative 54 5 N A
71% at 5 years
Similar survival rates between
curative versus palliative resection
(15) Osborne et al. [54] 2006 61 62% curative,
28% palliative 03 . 2 9 1 80% at 5 years (curative)
60% at 5 years; (palliative)
(16) Reddy et al. [41] 2006 33 70% curative,
30% palliative 94 2 N A
75% at 3 years;
Diﬀerences in survival between
curative and palliative resections
are not reported
(17) Hibi et al. [43] 2006 21 100% curative 0 19 100 41% at 5 years
(18) House et al. [37] 2006 26 100% curative 0 NA NA Median survival 78 months
(19) Gomez et al. [34] 2007 18 83% curative,
17% palliative 5.5 22 100
86% at 5 years
Diﬀerences in survival between
curative and palliative resections
are not reported
(20) Landry et al. [105] 2008 23 NA 0 26 NA 75% at 5 years
(21) Chambers et al.
[106] 2008 30 NA 0 22 86 74% at 5 years
(22) Ahmed et al. [107] 2009 50 NA 0 NA NA 74.3% at 5 years
Comments: Operative mortality and morbidity refer to ﬁgures for patients undergoing liver resections. Survival date is stated for the entire cohort (curative
and palliative resections), unless otherwise is stated. Symptom control includes both partial and complete response. NA means that information was not
provided in original paper.4 International Journal of Hepatology
Table 2: Case series of hepatic resections with ablation performed for neuroendocrine liver metastases.
Author Year N undergoing
resection/ablation
Operative
mortality (%)
Operative
morbidity
(%)
Symptom
control (%) Survival
(1) Mayo et al. [39] 2010 339 NA NA NA 74% at 5 years
(2) Glazer et al. [42] 2010 172 0 22.1 NA 77.4% at 5 years
50.4% at 10 years
(3) Strosberg et al. [108] 2009 31 NA NA NA 75% at 5 years; median
survival of 103 months
(4) Touzios et al. [27] 2005 19 5.2 42 95 72% at 5 years
(5) Musunuru et al. [31] 2006 13 NA NA 100 83% at 3 years
Some studies [22, 65, 102, 109] are excluded in the tables as the data is not stratiﬁed to liver resections and thus no meaningful data can be extracted for liver
resections.
liver resection for NELM are presented and summarized in
Table 1. Patients in whom hepatic resection was achievable
had a signiﬁcantly better median overall survival and 5-
year survival than those with unresectable hepatic disease
[26, 30, 31, 37] .T h em e d i a ns u r v i v a lr a n g e sf r o m5 2t o
123 months for patients who undergone resection of NELM
[20, 38].
In the major series attempting curative resection for
NELM, curative resection is achieved in a range of 22%
to 84% (Table 1)[ 16, 30]. Sarmiento at al. reported one
of the largest single center series on resection for NELM,
they achieved complete resection in 44% of their patients.
The main site of residual disease resulting in incomplete
resection was the liver (96%). They reported a morbidity of
14% and an operative mortality of 1.2%. Not surprisingly,
there is a signiﬁcant diﬀerence in recurrence rate in patients
with complete and incomplete resection (76% versus 91%
at 5 years; P = 0.0004) The overall survival rate for the
cohort of 170 patients at 5 and 10 years were 61% and 35%,
respectively and median survival was 81 months. Notably,
theydidnotdetectadiﬀerenceinsurvivalrateinpatientwith
or without preoperative endocrinopathy, although there was
no mention of any quality of life measures [19].
Mayo et al. reported the largest and the only multi-
institutional experience of surgical management of NELM.
In this study of 339 patients, the majority underwent
resection of the NELM (77.6%), 19.5% underwent resection
plus ablation, and in 2.9%, ablation was the only liver-
directed therapy performed. They achieved curative resec-
tion(R0 status)in53.7%ofthepatients.Intheirmultivariate
analysis,theyfoundinthosepatientsNETwithouthormonal
function, presence of synchronous disease, and concomitant
extrahepatic disease as negative prognostic factors. Patients
with a hormonally functional NET who had R0/R1 resection
beneﬁted the most from surgery. In this study, they achieved
an overall 5- and 10-year survival of 74 and 51% [39].
The diﬀerences in survival data must be interpreted
appropriately as the criteria of resectability are ever evolving
and there are major improvements in the safety of liver
resection, this must be taken into account when comparing
recent series to older studies [40].
It is important to highlight that even with an aggres-
sive policy and available expertise, conventional partial
hepatectomy is rarely possible, as approximately 90% of
metastases are multifocal and bilobar [6]. Even in the sce-
nario when complete resection of NLM is performed, early
recurrence is more common compared to other common
hepatic lesions such as colorectal metastases [40, 41].
The biological behaviour of NETs and their metastases
is variable, patients with NELM from bronchopulmonary
endocrine tumors are known to have the poorest prognoses
as compared to other sites [42, 43]. Patients with NELM
from a colonic primary seem to have a better recurrence free
survival when compared to the rest of the other sites [42].
Other than tumor site, independent preoperative factors for
a poor prognosis include tumor diﬀerentiation, pancreatic
tumor, nonfunctional primary tumor, presence of multiple
and/or bilobar liver metastases, and invasion of greater than
75% of the hepatic parenchyma [23, 29, 44].
There are studies comparing resection against other
formsoftherapyinanattempttoidentify asubsetofpatients
who will beneﬁt the most from surgery and to individu-
alize therapy regimes [45]. In a recent multi-institutional
study analyzing over 700 patients comparing liver resec-
tion versus intra-arterial therapy (including transarterial
chemoembolization, bland transarterial embolization, and
drug-eluting beads or yttrium-90) for NELM, they found
that although surgical management provided a survival ben-
eﬁt over intra-arterial therapy among symptomatic patients
with >25% liver involvement, there was no signiﬁcant
diﬀerence in long-term outcome. In this study, liver-directed
surgery includes resection and RFA or in combination.
They concluded that asymptomatic patients with a large
burden of liver disease beneﬁted the least from surgery
and nonsurgical liver-directed therapy like various forms
of intra-arterial therapy may be more appropriate. They
suggestedthatsurgicalresectionofNELMshouldbereserved
for patients with low-volume disease or for those patients
with symptomatic high-volume disease [20].
Although there is no signiﬁcant diﬀerence in disease
incidence worldwide, most of the studies on NELM are from
the West. There is only a single report from Asia reporting
a case series of 21 patients reporting a similar results and
conclusions. They report an overall 68% 3-year and a 41%
5-year survival rate for patients; those that achieved curative
resection have a signiﬁcantly better 5-year survival rate (73%International Journal of Hepatology 5
versus 0%, P = 0.01) compared to those who underwent
a palliative resection [43]. The group from M.D. Anderson
CancerCenterreportedrecentlyintheirstudyof172patients
undergoingsurgeryforNELMthattheyfoundthatinAsians,
on multivariate analysis, the recurrence free survival was
signiﬁcantly lower as compared to the rest of the study
population [42].
There is no evidence for the eﬀect of adjuvant treatment
of radically operated patients [46]. Medical treatment is
required only in the event that the tumour and/or its
metastases cannot be completely resected.
4. Palliative Liver Resection for
NET LiverMetastases
A distinguishing feature of these malignancies beside the
ability to metastasize is the potential for unregulated
endocrine activity. This fact complicates treatment but
serves as one of the main rationale for roles of palliative
surgery. Even when resection with curative intent is not
feasible, either due to the presence of extrahepatic disease
or extensive intrahepatic disease, there remains a role for
surgery, though this remains less well deﬁned. The goals of
palliative surgery focus on retardation of tumor cell growth,
relief of mass symptoms, symptoms of hormonal hyper-
secretion, prolonging survival, and ﬁnally achieving a good
quality of life on the long term.
Some authors have deﬁned cytoreductive hepatic surgery
as resection of 90% of the bulk of the tumour, and this
refers to the incomplete resection of tumor to reduce symp-
toms and facilitate the eﬀect of nonsurgical strategies [47].
DebuIking surgery is deﬁned as surgical resection with gross
residual disease beyond the criteria of cytoreductive surgery.
The Mayo Clinic group has recommended that palliative
resection is justiﬁed if at least 90% of hepatic metastases are
resectable, and the extrahepatic tumour bulk is limited [48].
This recommendation has also been advocated separately
in the consensus report of the European Neuroendocrine
Tumour Society [49]. Frilling et al. proposed that cytore-
ductive liver resections should be considered if there is no
evidence of unresectable extrahepatic disease and less than
70 percent of the liver is involved by tumour [22].
In the palliative setting, where symptomatic control for
quality of life and not extension of the survival is the
primary goal, the risk-beneﬁt ratio needs to be clearly
ascertained in order to justify surgery as liver resection is
not without its share of signiﬁcant morbidity and mortality.
If cytoreductive surgery can increase survival, then the
application of operative interventions is doubly justiﬁed
in a patient population that can survive many years with
symptomatic disease.
Neuroendocrine tumor behavior and biologic charac-
teristics exist to justify the application of cytoreductive
therapy. In the majority of NETs, the tumors have a long
doubling time, especially in gastrointestinal neuroendocrine
tumors where hepatic and regional nodal metastases are the
predominant site of spread. In the majority of metastatic
NETs, metastases are limited to the liver. They are susceptible
to chemotherapy and embolization, and the tumor volume
correlates with magnitude of disabling endocrine symptoms.
Crucially, the primary tumors are often resectable despite
extensive metastases [50]. The survival of patients with
gastrointestinal neuroendocrine tumors even with estab-
lished metastases is longer compared with that of patients
with other malignancies, up to 30 to 40% 5-year survival
without treatment. Metastatic patients with gastrointestinal
neuroendocrine tumors clearly have a better survival com-
pared to patients with metastatic adenocarcinoma of the
gastrointestinal tract [51, 52].
4.1.ResultsofPalliativeLiverResectionforNETLiverMetasta-
ses. Proponents of aggressive approaches advocating partial
hepatectomy, cytoreductive liver resection, and ablation cite
numerous many retrospective institutional studies reporting
palliation of symptoms and prolonged survival duration
among patients undergoing surgery with curative or near
curative intent (Table 1)[ 13, 17, 26, 53, 54].
However, to date, there have been no trials evaluating
these criteria in a prospective fashion. Furthermore, these
guidelines are neither universally accepted nor adopted,
and the majority of the literature consists of heterogeneous
cohorts, making interpretation and comparison of data
diﬃcult.
Advanced unresectable neuroendocrine tumours are as-
sociated with prolonged survival. Fifty percent of incurable
tumors survive 5 or more years after diagnosis. Median
survival of patients with unresectable hepatic metastases
ranges from 3 to 4 years, and nearly 30–40% of these patients
were alive at 5 years [52, 55].
Patients may suﬀer for prolonged periods from metasta-
ses-associated endocrinopathies, of which the severity of the
endocrinopathy parallels the tumor volume [48]. Although
there is an absence of a validated universal method for mea-
suring and comparing symptoms and their response to ther-
apy, the literature suggests that resection of neuroendocrine
hepatic liver metastases can result in excellent palliation of
hormone-related symptoms. In carefully selected patients,
partial or complete relief of systematic endocrine-related
symptoms can be achieved in more than 90% of subjects
undergoing cytoreductive or palliative liver resection, with
a correspondingly low morbidity and mortality [13, 19,
54]. Objectively, one study demonstrated a postoperative
reduction in urinary excretion of the serotonin metabolite
5-hydroxyendoleacetic acid (5-HIAA) which correlated with
the decrease in hormone-related symptoms of ﬂushing and
diarrhea[19].Assuch,surgeryforsymptomspalliationalone
is well justiﬁed.
After successful cytoreductive surgery, the mean dura-
tion of symptom reduction is between 16 to 26 months
[13, 56, 57]. Unfortunately, recurrence or progression of
symptoms can occur within 20–45 months, and the ﬁve year
recurrence/progression rate ranges from 59 to 76% [19, 57].
More than a decade ago, Que et al. showed that initial
symptomatic response is similar in patients with metastatic
disease whether resected with curative or palliative intent,
but recurrence of symptoms occurred earlier in patients
undergoing resection with palliative intent (11.3 months
versus 20.4 months). He further proposed that the duration6 International Journal of Hepatology
ofresponsecanbepredictedbythecompletenessofresection
and normalisation of hormonal markers in the immediate
postoperative period [13]. Hibi et al. reported the only
Asian series of liver resections for metastatic neuroendocrine
tumours. Seven patients (33% of the cohort) underwent
palliativeresection.Theresolutionofsymptomsaftersurgery
was complete in ﬁve patients, partial in one, and one was
asymptomatic preoperatively [43].
Sarmiento et al. have one of the largest single-institution
series of hepatic resections for metastatic neuroendocrine
tumours with 170 patients. This study included patients with
curative resections, but majority of the patients underwent
palliative resection (56%). They showed good response in
96% of patients with hormone-related symptoms, and all
these patients had at least 90% of gross hepatic disease
resected. In their series, symptom recurrence was 59%
at 5 years, with a median time to recurrence of 45.5
months, although these were appreciably less severe and
easily controlled with minimal doses of octreotide. They
reiterated the recommendation that aggressive resection for
palliation be pursued with a view to remove at least 90% of
gross disease and suggested that the increasing availability
and applicability of radiofrequency ablation would further
increase the pool of patients who could potentially beneﬁt
from a combined ablative policy [19].
Notwithstanding the fact that metastatic neuroendocrine
disease conﬁned to the liver is compatible with prolonged
survival,painordebilityduetohepatomegalyandsymptoms
from a variety of endocrinopathies from excessive hormone
production can impact negatively on patients’ quality of life
[51, 58]. There is a paucity of data looking speciﬁcally at
improvement in quality of life after surgery for NELM. One
study by Knox et al. did demonstrate an improvement in
quality of life as measured by Karnofsky performance score
by the third postoperative month which was sustained for
more than 4 years after surgery [59].
Radiofrequency ablation (RFA), transarterial chemoem-
bolisation (TACE), cryosurgery, and other ablative therapies
have been used for palliation, although a Cochrane review
in 2009 found no prospective randomized trials comparing
the results of surgery to those of any other method in the
palliation of metastatic neuroendocrine tumours to the liver
[21]. Bergen and Osborne compared resection outcomes
versus embolic treatment in symptomatic metastatic NET
and reported that cytoreductive surgery for metastatic
neuroendocrine tumors resulted in improved symptomatic
relief in terms of high proportion of complete (69% versus
59%) as well as a longer duration of relief. There is also
improved survival when compared with embolic therapy in
thisnonrandomizedretrospectivestudy.Theyrecommended
cytoreductive surgery should be pursued whenever possible
even if complete resection may not be achievable [60].
5. LiverTransplantationfor Neuroendocrine
LiverMetastases
Liver transplantation has a selected role in unresectable
NELM and is proposed for certain candidates with a 5-year
overall survival of up to 70% and 5-year recurrence free
survival of up to 50% [9]. In the largest meta-analysis of 103
patients, the 5-year survival rate was 47%, with only 24% of
patients free of disease recurrence [61]. The largest series of
livertransplantsforNELMwasthemulticenterFrenchstudy,
coordinatedbyLeTreutetal.whichreportedon85caseswith
an overall survival of 47% and a recurrence free survival of
20% at 5 years [62].
Mazzaferro et al. proposed a set of guidelines for the
selection of candidates for liver transplantation, now known
as the “Milan criteria” (Figure 1 inset) [9]. These guidelines
emphasized the requirement for a speciﬁc diagnosis of
endocrine tumors and considered patients who had well-
diﬀerentiated endocrine tumors with low-grade malignancy,
establishedonthebasisofmitoticandproliferationindicesas
eligible candidates for liver transplantation. In another con-
sensus guideline by the European Neuroendocrine Tumor
Society, patients with diﬀuse unresectable liver metastases or
thosewithlife-threateninghormonaldisturbancesrefractory
to medical therapy, liver transplantation may be a possible
treatment option for these selected patients. Due to the slow-
growing nature of NETs and their tendency to metastasize
only to the liver, NETs remain one of the few indications
for liver transplantation in metastatic disease, particularly
if living-related donation is feasible. They commented that
patients who are most likely to beneﬁt from liver trans-
plantation are those less than 50 years old who are free of
extrahepatic tumor and have low expression of Ki-67 and E-
cadherin [63]. The details and results of OLT for NELM are
beyond the scope of this paper but in brief, several factors
plague liver transplantation as an eﬀective treatment option.
Although liver transplantation has the theoretical advantage
of removing all tumor burden in patients beyond the criteria
for respectability, and advances in technique and improved
perioperative care have made liver transplantation safer
recently; early disease recurrence, signiﬁcant morbidity and
mortality, the absence of extensive experience, and shortage
of donor organs all contribute to preclude orthotopic
liver transplantation (OLT) as an eﬀective option for most
patients with unresectable NELM [64].
6. Combination Therapy
Palliation can also be achieved with a combination of treat-
ment modalities. Surgery can be combined with other ther-
apies, for example, antihormonal therapy, chemotherapy,
immunotherapy, and interventional radiological procedures,
eithersimultaneousorinstages.Theroleofadjuvanttherapy
and which modality will be optimal in complementing
palliative surgery is not well established.
T h e r ei ss o m ed a t ao nt h ee ﬃcacy of a cytoreduc-
tive strategy combining both surgery and RFA in the
same session (Table 2). Eriksson et al. showed that out
of the patients aggressively treated with a combination of
anatomical and nonanatomical resection with intraoperative
and percutaneous radiofrequency ablation, 70.6% of those
with carcinoid syndrome had partial or complete symptom
response.Theyalsofoundlargetumorsize,highpreoperative
Chromogranin A and 5-HIAA levels, and high Ki67 index to
be risk factors for recurrence [65]. Musunuru et al. showedInternational Journal of Hepatology 7
Isolated neuroendocrine liver metastases
(imaging with CT, MRI, and somatostatin scintigraphic scans)
Multidisciplinary meeting and discussion
Completely resectable by
surgery alone
Resection with curative intent
• Consider cholecystectomy
N o tr e s e c t a b l ew i t hs u r g e r y
alone
Able to ablate all disease
with a combination of
resection and RFA
(1) . <70% of the liver was
involved by tumour
(2)No evidence of
unresectable
extrahepatic tumour spread
Unable to ablate all disease
Resection and RFA with
curative intent
• Consider cholecystectomy
Cytoreductive resection +/−
RFA for symptom
relief/prolong survival
• Consider cholecystectomy
Candidate for
liver transplant∗
Able to resect/ablate ≥ 90%
of hepatic disease
Unable to resect/ablate ≥90%
of hepatic disease
Orthoptic
liver
transplant
Not
candidate for
transplant
Palliative
chemotherapy/
TACE/
octreotide
∗Milan criteria for suitability of neuroendocrine liver metastases for transplantation [9]
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
Conﬁrmed carcinoid histology
Primary tumor drained by portal system
50% hepatic replacement by tumor metastases
Good response or stable disease during the
pretransplantation period
Age les≤ than or equal
Exclusion criteria:
Small-cell carcinoma and high-grade neuroendocrine carcinomas (noncarcinoid tumors)
Other medical/surgical conditions contraindicating liver transplantation, including previous tumors
Nongastrointestinal carcinoids or tumors not drained by the portal system
Figure 1: Proposed Algorithm for management of isolated neuroendocrine liver metastases.
that compared to either medical therapy alone, systemic
chemotherapy, or transarterial embolization, a combination
of surgery and RFA resulted in 100% symptom control and
improved 3-year survival rate (83% versus 31%) [31].
7. Role of Prophylactic Cholecystectomy
The role of prophylactic cholecystectomy has been recom-
mended by some authors when surgery is considered for
an advanced neuroendocrine tumor [49]. The rationale for
prophylactic cholecystectomy during partial hepatectomy
for NELM includes (1) the fact that somatostatin analogs
may induce gallstone disease in up to 50% of cases;
(2) chemoembolization has a high risk for cholecystitis
occurrence; (3) in the event that the hepatic lesions are
not resectable and should the hepatic artery be ligated or
embolized to control symptoms, necrosis of the gallbladder
can potentially occur. Some authors cite these reasons to
justify the minimal morbidity from the additional procedure
[53, 66]. However, there are diﬀering opinions, in the
recent 2010 Nordic Guidelines, they commented that as the
somatostatin-induced bile stones usually are asymptomatic,
liver embolization techniques have improved considerably
and the risk of complications to cholecystectomy is up to
3%; taking these points into consideration, they did not
recommended prophylactic cholecystectomy.
8. SurgicalConsiderations
As neuroendocrine hepatic metastases are numerous and
often large, surgical resectability is a primary concern.
Once it has been established that curative or cytoreductive
resection is indicated, resectability can be determined from
two factors: anatomical feasibility and volumetric tolerance.
A multidisciplinary approach involving in the minimum a
liver surgeon and a dedicated hepatobiliary radiologist, a
medical oncologist is recommended to validate the decision.
8.1. Resectability of Neuroendocrine Liver Metastases. The
deﬁnition of “resectability” is determined by many factors
including patient, disease, and technical factors. The prin-
ciple lies in the technical ability to leave a remnant with
adequate function for sustaining life but consistent with
low perioperative morbidity and mortality and acceptable8 International Journal of Hepatology
long-term outcome in survival and quality of life. Relative
contraindications to partial hepatectomy include signiﬁcant
medical comorbidities, rapidly progressing intrahepatic dis-
ease, and progressive or extensive extrahepatic disease. The
golden rule for partial hepatectomy is to ensure enough liver
parenchyma with a satisfactory blood supply (hepatic artery,
portal vein, and hepatic vein), and biliary drainage remains
after resection so that the patient does develop postoperative
liver failure. Contraindications of liver metastasectomy are
situations in which the tumors have invaded the biliary
conﬂuence or invaded the three hepatic veins or the portal
bifurcation. Any scenario in which bilioenteric anastomosis
to the remaining bile ducts cannot be constructed is also
considered as a relative contraindication to resection. Fortu-
nately, the growth pattern of NELM permits an aggressive
surgical approach as the lesions are often discrete and the
masses displace rather than invade or encase the major
intrahepatic vessels or bile ducts. Some NELM have a miliary
pattern with or without dominant tumors, however, these
miliary metastases does not aﬀect the resectability of the
larger dominant tumors, and due to slow growth of the
tumors, resection of dominant NELM can be considered for
cytoreductive purposes for symptoms relief [50].
Theabilityofthenonpathologicallivertoregenerateafter
liver resection is good, and a remnant functional normal
liver tissue as little as 20 to 25% may be suﬃcient [67, 68].
The ratio of remnant functional liver to the initial total liver
tissuemaybediﬃculttoestimatebecauseofthehighnumber
and size of metastatic nodules; the volume of these tumors
shouldbeexcludedwhendeterminingthevolumeofthetotal
liver. There are studies that utilize volumetric ratio without
considering the total liver volume, but use percentage of
t o t a lb o d yw e i g h ti n s t e a d[ 69]. It has been demonstrated
that there is a risk of postoperative liver failure when the
remainingfunctionalliverratiofallstolessthan0.5%oftotal
body weight. Multidetector computed tomography (CT) of
the liver is usually applied to measure liver volumes. Most
surgeons will not advocate surgery if the estimated volume
of functional remnant liver is either less than 20–25% of
the total liver or less than 0.5% of total body weight. Other
than Child-Pugh scoring, Model for End-Stage Liver Disease
(MELD) and liver function test, some studies have validated
the use of indocyanine green clearance (ICG) as an objective
adjunct in assessing liver function, in our institution, we use
ICG selectively for patient with “borderline respectability”
[70–73]. In patients with “borderline respectability”, one
safer option is to induce hypertrophy in the remaining
functional liver via portal embolization to reduce the risk of
postoperative liverfailure. Compensatory hypertrophyofthe
contralateral lobe is generally observed in a period of three
to six weeks. Some studies report a high feasibility rate for
this strategy and report a mean gain in liver volume of over
40%, thus increasing the volumetric feasibility for resection
of hepatic metastases from NETs [74, 75]. In patients whose
NELM are bilobar, in line with aggressive approach, studies
have reported the two-stage hepatectomy strategy as a useful
alternativetoportalembolization.Thistechniqueenablesthe
successive treatment of the left lobar metastases followed by
those in the right lobe, with ligature of the right portal vein
in the ﬁrst stage of the surgery to induce hypertrophy of the
leftlobeduringthetimeintervalbetweenthetwooperations.
In the second stage, a right hepatectomy is performed with
the hypertrophied left lobe sustaining postoperative liver
function [75]. Some authors suggest a core biopsy should be
consideredpriorconsiderationforresection,inthesituations
when the health of the remnant liver is in doubt [42].
8.2. Role of Hepatic Lymphadenectomy in Neuroendocrine
Liver Metastases. T h er o l eo fh e p a t i cl y m p h a d e n e c t o m yi n
neuroendocrine liver metastases is not well established [76].
Most of the experience and data are extrapolated from col-
orectal liver metastasis (CLM), of which nodal involvement
of the hepatoduodenal ligament is an independent predictor
of survival following a curative partial hepatectomy [77–
79]. The Mayo Clinic identiﬁed metastatic hepatoduodenal
lymph nodes as an independent predictor of survival with
an almost 40% increase in 5-year survival (18.8% versus
58.1%) in node-negative patients following hepatectomy
for colorectal metastases [77] .AF r e n c hs t u d yo nl y m p h
node metastases in CLM reported a superior 3-year survival
of 38% in patients with nodal metastases limited to the
hepatoduodenal ligament and retropancreatic region, versus
no survivors beyond a year in patients with metastases to
the common hepatic artery and celiac axis region following
a hepatectomy; the authors concluded that a systematic
regional lymphadenectomy should be performed in patients
undergoing hepatectomy for CLM as it oﬀers prognostic
information, however, in the presence of metastases to
commonhepaticarteryandceliacaxisregion,ahepatectomy
may not be justiﬁed [80]. These data suggest that a regional
lymphadenectomy is important in all patients undergoing
a curative hepatectomy for malignant tumors for accurate
prognostication, selection of patients for adjuvant therapy,
and prospective evaluation of a potential survival beneﬁt.
However, there is little information on NELM, and there
is no consensus if the CLM experience is translatable
to NELM. Criteria for an adequate lymphadenectomy for
NELM including the extent and minimum number of lymph
nodes removed require further study.
8.3. Width of Resection Margins in Neuroendocrine Liver Me-
tastases. Another point of contention in the resection of
liver metastases is the optimal margin of resection. There
is no clear evidence or consensus on the width of clear
margins for NELMs. Generally for liver metastases, a positive
resection margin predisposes to marginal recurrences and
is an independent predictor of poor survival [81–84]. Most
of the experience and data are accumulated from colorectal
liver metastasis and extrapolated to other liver metastases
from other primaries, for example, NETs. The optimal width
of the resection margin is confounded by the diﬀerent
parenchymal transection techniques used at diﬀerent centers
[85]. The loss of a 5- to 8-mm tumor-free margin during
liver resection confounds the issue of adequacy of pathologic
margins and the use of contrast-enhanced intraoperative
ultrasound may enhance the accuracy of resection margins
[86, 87]. Comparisons of anatomic and wedge resections
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positive margins, recurrence patterns, or overall survival
[88–90]. Several series demonstrated that a positive resec-
tion margin is an independent predictor of poor survival
following hepatectomy for CLM, further to this, some
centers have demonstrated improved outcomes with more
than 1cm margins compared with narrower margins. The
Memorial Sloan Kettering Cancer Center, in their review of
1019 patients after hepatic resection for CLM, reported a
signiﬁcant decrease in the median survival of patients with
a positive margins of 1cm or less, and that a resection
margin of more than 1cm was an independent predictor
of survival [91]. In another report by Wakai et al. 95% of
the intrahepatic micrometastases were noted within 1cm of
the advancing edge of the metastatic tumor deposit and a
margin of 1cm or more was associated with signiﬁcantly
improved survival [92]. In view of this, some have suggested
that nonanatomic resection for CLM should at a minimum
attain negative pathologic margins with the goal of a 1cm
margin. In contrast, some authors report that the width
of the resection margin does not inﬂuence survival as long
as it is negative [86, 92–95]. Complete resection is the
goal of hepatectomy for neuroendocrine liver metastases
as the rate of recurrence and the median time to recur-
rence are negatively aﬀected by incomplete resection [13,
19, 23]. Agrawal and Belghiti have recently recommended
a resection margin of less than 1cm for noncolorectal
liver metastases, that is, neuroendocrine liver metastases
[96].
9. Perioperative Considerations
T h e r eh a v eb e e nh u g ei m p r o v e m e n t si ns u r g i c a la n da n e s -
thetic techniques and the perioperative management of these
patients, these contributed to signiﬁcant reductions in the
morbidity and mortality rates after partial hepatectomy.
Even in institutions reporting a signiﬁcant percentage of
complexhepatectomies,perioperativemortalityisapproach-
ing 1% to 3% in patients without underlying liver dys-
function [97]. Perioperative morbidity and mortality rates
for metasectomies of neuroendocrine tumors are similar
to those reported for colorectal metastases [13, 98]. The
surgery-related mortality of major series of hepatectomy for
NELM ranges from 0 to 9% (Table 1)[ 74]. The reported
overall morbidity rate ranged from 3% to 24% after partial
hepatectomy for NELM (Table 1).
Patient selection is important for safe hepatic surgery.
Patients with signiﬁcant comorbidities should be reviewed
by the anesthetic team for evaluation of preoperative risk
factors related to general health status (American Society of
Anesthesiologists (ASA) score) or associated diseases (e.g.
right cardiac failure in carcinoid syndrome). Perioperatively
or prior to any intervention, for example, radiofrequency
ablation, all patients should receive 100–150µg/h octreotide
intravenously for 12 hours prior procedure [22]. Alter-
natively, preoperative preparation with 150 to 500µgo f
somatostatin administered in the preinduction phase in the
operating theatre prevents hemodynamic instability intra-
operatively. Speciﬁc presurgery preparation may be neces-
sary for individual tumors for example, for insulinomas,
regularglucosemonitoringandforgastrinomas,H2-receptor
antagonistsorH+-K+ ATPaseinhibitorsareessential[50].An
endocrinologist consult preoperatively is recommended for
patients going for surgery with functional NETs.
In general, the perioperative risk is not increased with
speciﬁc endocrinopathies, with the exception of carcinoid
heart disease. Surgical repair of carcinoid heart disease may
be required prior to hepatic resection for symptomatic
carcinoid syndrome in selected patients to reduce the
risk of massive hemorrhage caused by intrahepatic venous
hypertension from right heart failure [99].
Perioperativemorbidityandmortalityaredirectlyrelated
to the postoperative liver remnant function, the most impor-
tant determinant of which is the extent of liver resection. In
patients with tumors located adjacent to vascular structures
or those with multiple lesions exist in separate distinct
locations, this group of patients are likely to require large
volume resections thus leaving small functional remnant
liver as a result. Many strategies have been suggested to cope
with this challenge; these include parenchyma-preserving,
segmental approaches to resection, incorporation of con-
comitant wedge excisions or thermal ablations for small
tumors outside the perceived safe ﬁeld of resection, and
the use of either preoperative portal vein embolization or
staged resections to induce hypertrophy of the future liver
remnant [100]. Besides liver-related complications, Glazer
et al. also reported severe postoperative complications, for
example, intra-abdominal ﬂuid collection as an independent
risk factor for perioperative mortality [42].
10. Discussion
The presence of liver metastases is a distinguishing feature
of malignant neuroendocrine tumors and is the rate-limiting
step on patient’s survival [101, 102]. Based on available
data (Tables 1 and 2), we advocate an aggressive surgical
policy and propose an evidence-based surgical management
algorithm (Figure 1). Surgery has a strong role in NELM
and should be the treatment of choice if patients are ﬁt
and disease factors allow for it in both the curative, as
well as palliative settings. Strategies to increase the limits
of resectability, for example right portal vein embolization
to induce hypertrophy of the remaining left lateral section
before right hepatectomy or staged hepatic resections, can
be considered especially in experienced centres. We propose
that a multidisciplinary meeting should be the platform for
decision making. In patients with curative lesions, curative
resection should be the 1st line treatment, if cure cannot be
achieved by surgery alone, ablative modalities, for example,
RFA can be combined with surgery to achieve “cure”.
Adjuvant systemic therapies and local ablative treatment
have a role in complementing surgery for disease control
but the exact role of each is not well established and
beyond the scope of this paper (Table 2). In the event, if
curative intent cannot be achieved, cytoreductive surgery
with or without ablation should be performed if at least
90% of the tumour load can be treated. If surgery and
ablation cannot achieve this 90%, liver transplantation is a
consideration, failing which best medical treatment should10 International Journal of Hepatology
be oﬀered for palliation, for example, TACE, Chemotherapy,
and octreotide.
A study from Germany further classiﬁed the diﬀerent
patterns of NELM; they deﬁned type I as single metastasis
of any size, type II as isolated metastatic bulk accompanied
by smaller deposits, with both liver lobes always involved,
and type III as disseminated metastatic spread, with both
liver lobes always involved with virtually no normal liver
parenchyma. With this classiﬁcation, they found that the 3
types of NELM diﬀer in behaviour and biology and are the
only signiﬁcant independent predictor of survival [22]. This
study illustrates that although in general an aggressive ther-
apy is recommended, individualization of treatment strategy
should be tailored to each patient as some will beneﬁt more
from surgery for NELM than others [20]; a multidisciplinary
team approach should be the platform for this decision-
making process (Figure 1). The experts participating in such
a team can comprise of endocrinologists, gastroenterolo-
gists, hepatobiliary surgeons, pathologists, diagnostic and
interventional radiologists, medical oncologists, and nuclear
medicine physicians.
Adjuvant therapy is currently not indicated in patients
with completely resected NETs, and this need to be fur-
ther studied in clinical trials [46]. Development of tumor
repositoriesandclinicaldatabasesshouldhelpprovideuseful
information to facilitate the development of future studies.
Analysis of such data should also help identify patient
subgroups at particularly high risk of recurrence and to
validate scoring systems to help predict those patients most
likely to beneﬁt [23]. The development of standardized
histopathological and staging criteria should also improve
the selection of appropriate patients for clinical studies.
11. Conclusions
An aggressive surgical approach leads to long-term survival
in patients with NELM. Although long-term cure can only
be achieved in a proportion of patients with malignant
NETs, signiﬁcant long-term palliation can be achieved. This
aggressive surgical approach can be recommended, keeping
in mind that additional liver-directed procedures may be
required or combined with surgery to achieve eﬀectiveness
for a good quality of life. A multidisciplinary approach in
lieu of future prospective, randomized long-term followup
studiesshouldbeestablishedtoidentifythegroupofpatients
w h ow i l lm o s tb e n e ﬁ tf r o ms u r g e r yf o rN E L M .
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